Global Reperfusion Injury Market
Global Reperfusion Injury Market

Reperfusion Injury Comprehensive Study by Application (Heart Injury, Kidney Injury, Intestine Injury, Others), Treatment Type (Therapeutic Hypothermia, Cyclosporin, Stem Cell Therapy, Hydrogen SulfideTreatment, Others), End-Use (Hospitals, Nursing Homes, Clinics, Ambulatory Centers) Players and Region - Global Market Outlook to 2026

Reperfusion Injury Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

May 2021 Edition 204 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Reperfusion Injury Market Overview:
Reperfusion injury is tissue damage caused by a lack of blood supply or oxygen, such as damage to the brain after a stroke or the heart after an episode of ischemia. Instead of normal functioning, this type of blood supply restoration causes inflammation and oxidative damage by inducing oxidative stress. Prompt restoration of blood supply to the myocardium can result in smaller infarct size and lower mortality. This restoration, however, is known to cause heart damage and, finally, reperfusion injury. Such damage has been linked to a delay in reperfusion therapy.the global ischemia-reperfusion injury therapeutics market is expected to grow due to an increase in the number of tissue damage cases and increased awareness about ischemia-reperfusion injury. Furthermore, prominent companies are expected to increase their spending in the research and development of novel treatments for ischemia-reperfusion, which is expected to enhance the market growth. Some of the players profiled in the study are PharmaDrug Inc (Canada), Omeros Corporation (United States), Nyken B.V (Netherlands), Opsona Therapeutics Limited (Ireland), Pharming Group N.V. (Netherlands), Orexo AB (Switzerland), Egetis Therapeutics (Sweden), Proteo, Inc. (United States), Zealand Pharma A/S (Denmark) and Bayer AG (Germany).

On the basis of geography, the market of Reperfusion Injury has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment Type, the sub-segment i.e. Therapeutic Hypothermia will boost the Reperfusion Injury market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-Use, the sub-segment i.e. Hospitals will boost the Reperfusion Injury market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers
  • Increasing Incidents of Reperfusion Injury
  • Increase in the Geriatric Population
  • Growing Awareness about Heart Problems


Restraints
  • High Cost of the Reperfusion Injury Treatment

Opportunities
  • Rising Research & Development Activities
  • Increasing Investment in Healthcare Industry

Challenges
  • Stringent Regulatory Challenges


Key Market Developments:


April 2021 Ė PharmaDrug Announces First FDA Orphan Drug Designation of DMT for the Prevention of Ischemia-Reperfusion Injury from Organ Transplantation

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Target Audience:
Pharmaceutical companies, Research Companies, Healthcare Industry, Medical Research Companies and Others

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Reperfusion Injury market on the basis of product [] , application [Heart Injury, Kidney Injury, Intestine Injury and Others], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Reperfusion Injury market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Reperfusion Injury industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Prolong Pharmaceuticals (United States), Amyndas Pharmaceuticals (United States) and Prothix BV (Netherlands).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Reperfusion Injury market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Report Objectives / Segmentation Covered
By Application
  • Heart Injury
  • Kidney Injury
  • Intestine Injury
  • Others
By Treatment Type
  • Therapeutic Hypothermia
  • Cyclosporin
  • Stem Cell Therapy
  • Hydrogen SulfideTreatment
  • Others

By End-Use
  • Hospitals
  • Nursing Homes
  • Clinics
  • Ambulatory Centers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidents of Reperfusion Injury
      • 3.2.2. Increase in the Geriatric Population
      • 3.2.3. Growing Awareness about Heart Problems
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Challenges
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Reperfusion Injury, by Application, Treatment Type, End-Use and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Reperfusion Injury (Value)
      • 5.2.1. Global Reperfusion Injury by: Application (Value)
        • 5.2.1.1. Heart Injury
        • 5.2.1.2. Kidney Injury
        • 5.2.1.3. Intestine Injury
        • 5.2.1.4. Others
      • 5.2.2. Global Reperfusion Injury by: Treatment Type (Value)
        • 5.2.2.1. Therapeutic Hypothermia
        • 5.2.2.2. Cyclosporin
        • 5.2.2.3. Stem Cell Therapy
        • 5.2.2.4. Hydrogen SulfideTreatment
        • 5.2.2.5. Others
      • 5.2.3. Global Reperfusion Injury by: End-Use (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Nursing Homes
        • 5.2.3.3. Clinics
        • 5.2.3.4. Ambulatory Centers
      • 5.2.4. Global Reperfusion Injury Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Reperfusion Injury: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. PharmaDrug Inc (Canada)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Omeros Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Nyken B.V (Netherlands)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Opsona Therapeutics Limited (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pharming Group N.V. (Netherlands)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Orexo AB (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Egetis Therapeutics (Sweden)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Proteo, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Zealand Pharma A/S (Denmark)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bayer AG (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Reperfusion Injury Sale, by Application, Treatment Type, End-Use and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Reperfusion Injury (Value)
      • 7.2.1. Global Reperfusion Injury by: Application (Value)
        • 7.2.1.1. Heart Injury
        • 7.2.1.2. Kidney Injury
        • 7.2.1.3. Intestine Injury
        • 7.2.1.4. Others
      • 7.2.2. Global Reperfusion Injury by: Treatment Type (Value)
        • 7.2.2.1. Therapeutic Hypothermia
        • 7.2.2.2. Cyclosporin
        • 7.2.2.3. Stem Cell Therapy
        • 7.2.2.4. Hydrogen SulfideTreatment
        • 7.2.2.5. Others
      • 7.2.3. Global Reperfusion Injury by: End-Use (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Nursing Homes
        • 7.2.3.3. Clinics
        • 7.2.3.4. Ambulatory Centers
      • 7.2.4. Global Reperfusion Injury Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Reperfusion Injury: by Application(USD Million)
  • Table 2. Reperfusion Injury Heart Injury , by Region USD Million (2015-2020)
  • Table 3. Reperfusion Injury Kidney Injury , by Region USD Million (2015-2020)
  • Table 4. Reperfusion Injury Intestine Injury , by Region USD Million (2015-2020)
  • Table 5. Reperfusion Injury Others , by Region USD Million (2015-2020)
  • Table 6. Reperfusion Injury: by Treatment Type(USD Million)
  • Table 7. Reperfusion Injury Therapeutic Hypothermia , by Region USD Million (2015-2020)
  • Table 8. Reperfusion Injury Cyclosporin , by Region USD Million (2015-2020)
  • Table 9. Reperfusion Injury Stem Cell Therapy , by Region USD Million (2015-2020)
  • Table 10. Reperfusion Injury Hydrogen SulfideTreatment , by Region USD Million (2015-2020)
  • Table 11. Reperfusion Injury Others , by Region USD Million (2015-2020)
  • Table 12. Reperfusion Injury: by End-Use(USD Million)
  • Table 13. Reperfusion Injury Hospitals , by Region USD Million (2015-2020)
  • Table 14. Reperfusion Injury Nursing Homes , by Region USD Million (2015-2020)
  • Table 15. Reperfusion Injury Clinics , by Region USD Million (2015-2020)
  • Table 16. Reperfusion Injury Ambulatory Centers , by Region USD Million (2015-2020)
  • Table 17. South America Reperfusion Injury, by Country USD Million (2015-2020)
  • Table 18. South America Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 19. South America Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 20. South America Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 21. Brazil Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 22. Brazil Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 23. Brazil Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 24. Argentina Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 25. Argentina Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 26. Argentina Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 27. Rest of South America Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 28. Rest of South America Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 29. Rest of South America Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 30. Asia Pacific Reperfusion Injury, by Country USD Million (2015-2020)
  • Table 31. Asia Pacific Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 32. Asia Pacific Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 33. Asia Pacific Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 34. China Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 35. China Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 36. China Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 37. Japan Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 38. Japan Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 39. Japan Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 40. India Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 41. India Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 42. India Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 43. South Korea Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 44. South Korea Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 45. South Korea Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 46. Taiwan Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 47. Taiwan Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 48. Taiwan Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 49. Australia Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 50. Australia Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 51. Australia Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 55. Europe Reperfusion Injury, by Country USD Million (2015-2020)
  • Table 56. Europe Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 57. Europe Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 58. Europe Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 59. Germany Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 60. Germany Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 61. Germany Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 62. France Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 63. France Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 64. France Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 65. Italy Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 66. Italy Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 67. Italy Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 68. United Kingdom Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 69. United Kingdom Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 70. United Kingdom Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 71. Netherlands Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 72. Netherlands Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 73. Netherlands Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 74. Rest of Europe Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 75. Rest of Europe Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 76. Rest of Europe Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 77. MEA Reperfusion Injury, by Country USD Million (2015-2020)
  • Table 78. MEA Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 79. MEA Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 80. MEA Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 81. Middle East Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 82. Middle East Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 83. Middle East Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 84. Africa Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 85. Africa Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 86. Africa Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 87. North America Reperfusion Injury, by Country USD Million (2015-2020)
  • Table 88. North America Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 89. North America Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 90. North America Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 91. United States Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 92. United States Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 93. United States Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 94. Canada Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 95. Canada Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 96. Canada Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 97. Mexico Reperfusion Injury, by Application USD Million (2015-2020)
  • Table 98. Mexico Reperfusion Injury, by Treatment Type USD Million (2015-2020)
  • Table 99. Mexico Reperfusion Injury, by End-Use USD Million (2015-2020)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Reperfusion Injury: by Application(USD Million)
  • Table 111. Reperfusion Injury Heart Injury , by Region USD Million (2021-2026)
  • Table 112. Reperfusion Injury Kidney Injury , by Region USD Million (2021-2026)
  • Table 113. Reperfusion Injury Intestine Injury , by Region USD Million (2021-2026)
  • Table 114. Reperfusion Injury Others , by Region USD Million (2021-2026)
  • Table 115. Reperfusion Injury: by Treatment Type(USD Million)
  • Table 116. Reperfusion Injury Therapeutic Hypothermia , by Region USD Million (2021-2026)
  • Table 117. Reperfusion Injury Cyclosporin , by Region USD Million (2021-2026)
  • Table 118. Reperfusion Injury Stem Cell Therapy , by Region USD Million (2021-2026)
  • Table 119. Reperfusion Injury Hydrogen SulfideTreatment , by Region USD Million (2021-2026)
  • Table 120. Reperfusion Injury Others , by Region USD Million (2021-2026)
  • Table 121. Reperfusion Injury: by End-Use(USD Million)
  • Table 122. Reperfusion Injury Hospitals , by Region USD Million (2021-2026)
  • Table 123. Reperfusion Injury Nursing Homes , by Region USD Million (2021-2026)
  • Table 124. Reperfusion Injury Clinics , by Region USD Million (2021-2026)
  • Table 125. Reperfusion Injury Ambulatory Centers , by Region USD Million (2021-2026)
  • Table 126. South America Reperfusion Injury, by Country USD Million (2021-2026)
  • Table 127. South America Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 128. South America Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 129. South America Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 130. Brazil Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 131. Brazil Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 132. Brazil Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 133. Argentina Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 134. Argentina Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 135. Argentina Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 136. Rest of South America Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 137. Rest of South America Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 138. Rest of South America Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 139. Asia Pacific Reperfusion Injury, by Country USD Million (2021-2026)
  • Table 140. Asia Pacific Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 141. Asia Pacific Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 142. Asia Pacific Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 143. China Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 144. China Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 145. China Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 146. Japan Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 147. Japan Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 148. Japan Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 149. India Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 150. India Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 151. India Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 152. South Korea Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 153. South Korea Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 154. South Korea Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 155. Taiwan Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 156. Taiwan Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 157. Taiwan Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 158. Australia Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 159. Australia Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 160. Australia Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 161. Rest of Asia-Pacific Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 162. Rest of Asia-Pacific Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 163. Rest of Asia-Pacific Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 164. Europe Reperfusion Injury, by Country USD Million (2021-2026)
  • Table 165. Europe Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 166. Europe Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 167. Europe Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 168. Germany Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 169. Germany Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 170. Germany Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 171. France Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 172. France Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 173. France Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 174. Italy Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 175. Italy Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 176. Italy Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 177. United Kingdom Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 178. United Kingdom Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 179. United Kingdom Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 180. Netherlands Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 181. Netherlands Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 182. Netherlands Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 183. Rest of Europe Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 184. Rest of Europe Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 185. Rest of Europe Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 186. MEA Reperfusion Injury, by Country USD Million (2021-2026)
  • Table 187. MEA Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 188. MEA Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 189. MEA Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 190. Middle East Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 191. Middle East Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 192. Middle East Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 193. Africa Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 194. Africa Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 195. Africa Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 196. North America Reperfusion Injury, by Country USD Million (2021-2026)
  • Table 197. North America Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 198. North America Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 199. North America Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 200. United States Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 201. United States Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 202. United States Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 203. Canada Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 204. Canada Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 205. Canada Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 206. Mexico Reperfusion Injury, by Application USD Million (2021-2026)
  • Table 207. Mexico Reperfusion Injury, by Treatment Type USD Million (2021-2026)
  • Table 208. Mexico Reperfusion Injury, by End-Use USD Million (2021-2026)
  • Table 209. Research Programs/Design for This Report
  • Table 210. Key Data Information from Secondary Sources
  • Table 211. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Reperfusion Injury: by Application USD Million (2015-2020)
  • Figure 5. Global Reperfusion Injury: by Treatment Type USD Million (2015-2020)
  • Figure 6. Global Reperfusion Injury: by End-Use USD Million (2015-2020)
  • Figure 7. South America Reperfusion Injury Share (%), by Country
  • Figure 8. Asia Pacific Reperfusion Injury Share (%), by Country
  • Figure 9. Europe Reperfusion Injury Share (%), by Country
  • Figure 10. MEA Reperfusion Injury Share (%), by Country
  • Figure 11. North America Reperfusion Injury Share (%), by Country
  • Figure 12. Global Reperfusion Injury share by Players 2020 (%)
  • Figure 13. Global Reperfusion Injury share by Players (Top 3) 2020(%)
  • Figure 14. Global Reperfusion Injury share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. PharmaDrug Inc (Canada) Revenue, Net Income and Gross profit
  • Figure 17. PharmaDrug Inc (Canada) Revenue: by Geography 2020
  • Figure 18. Omeros Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 19. Omeros Corporation (United States) Revenue: by Geography 2020
  • Figure 20. Nyken B.V (Netherlands) Revenue, Net Income and Gross profit
  • Figure 21. Nyken B.V (Netherlands) Revenue: by Geography 2020
  • Figure 22. Opsona Therapeutics Limited (Ireland) Revenue, Net Income and Gross profit
  • Figure 23. Opsona Therapeutics Limited (Ireland) Revenue: by Geography 2020
  • Figure 24. Pharming Group N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 25. Pharming Group N.V. (Netherlands) Revenue: by Geography 2020
  • Figure 26. Orexo AB (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Orexo AB (Switzerland) Revenue: by Geography 2020
  • Figure 28. Egetis Therapeutics (Sweden) Revenue, Net Income and Gross profit
  • Figure 29. Egetis Therapeutics (Sweden) Revenue: by Geography 2020
  • Figure 30. Proteo, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Proteo, Inc. (United States) Revenue: by Geography 2020
  • Figure 32. Zealand Pharma A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 33. Zealand Pharma A/S (Denmark) Revenue: by Geography 2020
  • Figure 34. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 35. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 36. Global Reperfusion Injury: by Application USD Million (2021-2026)
  • Figure 37. Global Reperfusion Injury: by Treatment Type USD Million (2021-2026)
  • Figure 38. Global Reperfusion Injury: by End-Use USD Million (2021-2026)
  • Figure 39. South America Reperfusion Injury Share (%), by Country
  • Figure 40. Asia Pacific Reperfusion Injury Share (%), by Country
  • Figure 41. Europe Reperfusion Injury Share (%), by Country
  • Figure 42. MEA Reperfusion Injury Share (%), by Country
  • Figure 43. North America Reperfusion Injury Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • PharmaDrug Inc (Canada)
  • Omeros Corporation (United States)
  • Nyken B.V (Netherlands)
  • Opsona Therapeutics Limited (Ireland)
  • Pharming Group N.V. (Netherlands)
  • Orexo AB (Switzerland)
  • Egetis Therapeutics (Sweden)
  • Proteo, Inc. (United States)
  • Zealand Pharma A/S (Denmark)
  • Bayer AG (Germany)
Additional players considered in the study are as follows:
Prolong Pharmaceuticals (United States) , Amyndas Pharmaceuticals (United States) , Prothix BV (Netherlands)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation